Link: http://www.statnews.com/pharmalot/2016/03/15/valeant-drug-prices/

——————–

At STAT (website and news service for the pharma industry and pharma equity
analysts), on Valeant losing half its market value in one morning:

“Its business model wasn’t sustainable,” said Erik Gordon, a business and
law professor at the University of Michigan. “But you have to hope that its
fiery crash doesn’t discourage entrepreneurs from experimenting with other
new models, because it is not clear that the mainstream pharma model is the
best one to address the new realities of healthcare.”

Valeant slashes financial outlook; investors flee ‘a broken company’

—
_____________________
Erik Gordon
Ross School of Business
University of Michigan
Ann Arbor, Michigan